The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States.
Ruchi S Gupta, Christopher M Warren, Bridget M Smith...
https://pubmed.ncbi.nlm.nih.gov/30455345Actively Recruiting
Led by Medical University of Warsaw · Updated on 2024-05-20
39
Participants Needed
1
Research Sites
52 weeks
Total Duration
The trial investigates low-dose oral immunotherapy (OIT) using sesame protein in children aged 3 to 17 years with confirmed IgE-mediated sesame allergy. It compares this treatment with standard care, which involves an elimination diet and emergency treatment. The goal is to assess whether OIT can increase tolerance to sesame and improve safety outcomes in this pediatric population. Participants are randomly assigned in a 2:1 ratio to either receive OIT with a daily maintenance dose of 300 mg sesame protein mixed with fruit mousse or bread, or to follow a control group that maintains a strict elimination diet without OIT. The OIT group undergoes a build-up phase lasting up to 14 months followed by 3 months of maintenance treatment. The control group is observed for one year without immunotherapy. During the study, children will be monitored for ability to tolerate sesame protein through oral food challenges, adverse events, and changes in immune responses measured by laboratory tests, skin prick tests, and basophil activation tests. The primary outcome measures tolerance to a 4000 mg dose of sesame protein up to 18 months after starting treatment. Safety and immune response data will also be collected during this period. Total participation lasts up to 18 months, with ongoing assessments throughout.
CONDITIONS
Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 18 months
Participants receive daily low-dose sesame oral immunotherapy or follow a sesame avoidance diet, depending on their group assignment.
Regular visits for monitoring throughout treatment
Total: 1 location
1
Medical University of Warsaw
Warsaw, Masovian Voivodeship, Poland, 02-091
Actively Recruiting
K
Katarzyna Grzela, PhD, MD
J
Joanna Zielińska, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ruchi S Gupta, Christopher M Warren, Bridget M Smith...
https://pubmed.ncbi.nlm.nih.gov/30455345Christopher M Warren, Jialing Jiang, Ruchi S Gupta
https://pubmed.ncbi.nlm.nih.gov/32067114Ruchi S Gupta, Christopher M Warren, Bridget M Smith...
https://pubmed.ncbi.nlm.nih.gov/30646188Scott H Sicherer, Christopher M Warren, Christopher Dant...
https://pubmed.ncbi.nlm.nih.gov/32499034Ilan Dalal, Michael Goldberg, Yitzhak Katz
https://pubmed.ncbi.nlm.nih.gov/22610362Nicholas J Osborne, Jennifer J Koplin, Pamela E Martin...
https://pubmed.ncbi.nlm.nih.gov/21377036Christopher M Warren, Avneet S Chadha, Scott H Sicherer...
https://pubmed.ncbi.nlm.nih.gov/31373655Darit Aaronov, Diana Tasher, Arie Levine...
https://pubmed.ncbi.nlm.nih.gov/19119709Liat Nachshon, Michael R Goldberg, Michael B Levy...
https://pubmed.ncbi.nlm.nih.gov/31150789Philippe Bégin, Lisa C Winterroth, Tina Dominguez...
https://pubmed.ncbi.nlm.nih.gov/24428859